18th July 2017


Full Ambition in Accelerated Access Review ‘still to be realised’ 


LONDON, UK (18 July 2017)  - Commenting on the Government’s announcement on the Accelerated Access Review (AAR) and its commitment to increase funding in key areas, Chris Hudson, Director of Healthcare Development Roche Diagnostics UK, said:

“While we welcome the Government’s commitment to increase funding in certain areas, the full ambition in the AAR to improve access to medical technologies and diagnostic tools, is still to be realised.

“The AAR found that innovative diagnostics can save money and improve patient pathways. Around 70% of clinical decisions are made using some form of in vitro diagnostic.  However, currently the uptake of new in vitro diagnostics by the NHS can take up to 10 years, even though they are proven to reduce hospital stays and lead to better patient outcomes

 “We would welcome a full, positive Government response to the review ahead of the Industrial Life Sciences Strategy which will ensure  a sustainable healthcare system as highlighted in the Five Year Forward View “


For more details please contact roche@fourcommunications.com

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.